The effect of testosterone therapy on erectile dysfunction in type 2 diabetic patients.

IF 1.8 4区医学 Q3 UROLOGY & NEPHROLOGY

International Urology and Nephrology Pub Date : 2025-07-03 DOI:10.1007/s11255-025-04630-y

Alireza Akhavan Rezayat, Salman Soltani, Amirabbas Asadpour, Neda Kamandi, Amirmohammad Soleimanian

{"title":"The effect of testosterone therapy on erectile dysfunction in type 2 diabetic patients.","authors":"Alireza Akhavan Rezayat, Salman Soltani, Amirabbas Asadpour, Neda Kamandi, Amirmohammad Soleimanian","doi":"10.1007/s11255-025-04630-y","DOIUrl":null,"url":null,"abstract":"Introduction: Erectile dysfunction (ED) is commonly observed in Type 2 diabetic men, affecting approximately 75% of this demographic. Evidence suggests that phosphodiesterase-5 (PDE-5) inhibitors have limited therapeutic effects on progressive ED in men with Type 2 diabetes, indicating the need for alternative treatment lines. This study aims to investigate the effects of testosterone therapy on ED in Type 2 diabetic patients with normal testosterone levels.Materials and methods: This single-blind randomized clinical trial was conducted on Type 2 diabetic men with normal testosterone levels and erectile dysfunction. The control group received standard treatment with tadalafil 20 mg two hours before intercourse. In contrast, the intervention group, in addition to tadalafil, received 250 mg of intramuscular testosterone at 3 points (the start, and at 1 and 2 months afterwards. Informed consent was obtained, and participants were selected based on inclusion and exclusion criteria.Findings: A total of 60 Type 2 diabetic patients with ED were included, with an average age of 50.4 ± 9.7 years. Significant differences were observed between the intervention and control groups in terms of average total testosterone and International Index of Erectile Function (IIEF) scores (P value < 0.01), with the intervention group showing higher averages. These differences were also significant over time (P value < 0.01), indicating improved outcomes concerning the baseline.Conclusion: Testosterone therapy in diabetic men led to improvements in sexual desire and ED without adverse effects on liver function.","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urology and Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11255-025-04630-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Erectile dysfunction (ED) is commonly observed in Type 2 diabetic men, affecting approximately 75% of this demographic. Evidence suggests that phosphodiesterase-5 (PDE-5) inhibitors have limited therapeutic effects on progressive ED in men with Type 2 diabetes, indicating the need for alternative treatment lines. This study aims to investigate the effects of testosterone therapy on ED in Type 2 diabetic patients with normal testosterone levels.

Materials and methods: This single-blind randomized clinical trial was conducted on Type 2 diabetic men with normal testosterone levels and erectile dysfunction. The control group received standard treatment with tadalafil 20 mg two hours before intercourse. In contrast, the intervention group, in addition to tadalafil, received 250 mg of intramuscular testosterone at 3 points (the start, and at 1 and 2 months afterwards. Informed consent was obtained, and participants were selected based on inclusion and exclusion criteria.

Findings: A total of 60 Type 2 diabetic patients with ED were included, with an average age of 50.4 ± 9.7 years. Significant differences were observed between the intervention and control groups in terms of average total testosterone and International Index of Erectile Function (IIEF) scores (P value < 0.01), with the intervention group showing higher averages. These differences were also significant over time (P value < 0.01), indicating improved outcomes concerning the baseline.

Conclusion: Testosterone therapy in diabetic men led to improvements in sexual desire and ED without adverse effects on liver function.

查看原文本刊更多论文

睾酮治疗对2型糖尿病患者勃起功能障碍的影响。

勃起功能障碍（ED）在2型糖尿病男性中很常见，影响了大约75%的这一人群。有证据表明，磷酸二酯酶-5 （PDE-5）抑制剂对2型糖尿病男性进行性ED的治疗效果有限，表明需要其他治疗方法。本研究旨在探讨睾酮治疗对睾酮水平正常的2型糖尿病患者ED的影响。材料与方法：本试验为单盲随机临床试验，研究对象为睾酮水平正常且勃起功能障碍的2型糖尿病男性。对照组患者在性交前2小时给予他达拉非20 mg的标准治疗。相比之下，干预组除他达拉非外，在3个点（开始、1个月和2个月后）接受250 mg肌肉注射睾酮。获得知情同意，并根据纳入和排除标准选择参与者。结果：共纳入60例2型糖尿病合并ED患者，平均年龄50.4±9.7岁。干预组平均睾酮总水平、国际勃起功能指数（IIEF）评分与对照组比较差异有统计学意义（P值）。结论：睾酮治疗对糖尿病男性患者的性欲和ED均有改善，且对肝功能无不良影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Urology and Nephrology 医学-泌尿学与肾脏学

CiteScore

3.40

自引率

5.00%

发文量

329

审稿时长

1.7 months

期刊介绍： International Urology and Nephrology publishes original papers on a broad range of topics in urology, nephrology and andrology. The journal integrates papers originating from clinical practice.